Celecoxib, a cyclooxygenase-2 inhibitor, improved upper gastrointestinal lesions in rheumatoid arthritis patients as assessed by endoscopic evaluation

References

• Lain L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001;120: 594–606.
   PubMed Web of Science ®Google Scholar
• Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA, Laine L. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287:337–44.
   PubMed Web of Science ®Google Scholar
• Shiokawa Y, Nobunaga M, Saito T, Asaki S, Ogawa N. Epide-miology study on upper gastrointestinal lesions induced by non-steroidal anti-inflammatory drugs (in Japanese). Ryumachi. 1991;31:96–111.
   Google Scholar
• Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med. 1998;105(1B):315–85.
   Google Scholar
• Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med. 1999; 340:1888–99.
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991; 115:787–96.
   Google Scholar
• Hernandez-Diaz S, Rodriguez LA. Association between nonste-roidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies pub-lished in the 1990s. Arch Intern Med. 2000;160: 2093–9.
   Google Scholar
• Tomita T, Ochi T, Sugano K, Uemura S, Makuch RW. System-atic review of NSAID-induced adverse reactions in patients with rheumatoid arthritis in Japan. Mod Rheumatol. 2003;13: 143–52.
   Google Scholar
• Rahme E, Toubouti Y, Hunsche E. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Qubec, Canada. Rheumatology. 2006;45: 903–10.
   Google Scholar
• Langman M, Kahler KH, Kong SX, Zhang Q, Finch E, Bentkover JD, et al. Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs. Pharmacoepidemiol Drug Sat'. 2001;10:517–24.
   PubMed Web of Science ®Google Scholar
• Sift R, van Staa TP, Abenhaim L, Ebner D. A study of the lon-gitudinal utilization and switching-patterns of non-steroidal anti-inflammatory drugs using a pharmacy based approach. Pharma-coepidemiol Drug Sat'. 1997;6:263–8.
   PubMed Web of Science ®Google Scholar
• Walker AM, Chan KW, Yood RA. Patterns of interchange in the dispensing of non-steroidal anti-inflammatory drugs. J Clin Epidemiol. 1992;45:187–95.
   Google Scholar
• Garcia Rodriguez LA, Baneales Tolosa L. Risk of upper gas-trointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology. 2007;132:498–506.
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with non-steroidal anti-inflammatory drugs. Lancet. 1994;343:769–72.
   PubMed Web of Science ®Google Scholar
• Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, et al. Risk of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994; 343:1075–8.
   PubMed Web of Science ®Google Scholar
• Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized con-trolled trial. JAMA. 1999;282:1921–8.
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol. 2001;96: 1019–27.
   PubMed Web of Science ®Google Scholar
• Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lan-cet. 1999;354:2106–11.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K, Burke TA, Zhao SZ. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal anti-inflammatory drugs: a longitudinal study of 3639 patients in community practice. J Rheumatol. 2004;31:355–8.
   PubMed Web of Science ®Google Scholar
• Zhao SZ, Wentworth C, Burke TA, Makuch RW. Drug switching patterns among patients with rheumatoid arthritis and osteoar-thritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiol Drug Sat'. 2004;13:277–87.
   PubMed Web of Science ®Google Scholar
• Harley C, Wagner S. Persistence with COX-2 inhibitors in managed care: an analysis of claims data. Manag Care Interface. 2003;16:38–45.
   PubMedGoogle Scholar
• Moride Y, Ducruet T, Rochon S, Lavoie F. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec. Rheumatology 2003;42[Suppl 3]:iii17–22.
   Google Scholar
• Robinson MG, Griffin JW Jr, Bowers J, Kogan FJ, Kogut DG, Lanza FL, et al. Effect of ranitidine gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci. 1989;34:424–8.
   PubMed Web of Science ®Google Scholar
• Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med. 1996;334:1435–9.
   PubMed Web of Science ®Google Scholar
• Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastro-intestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. Br Med J. 2004;329:948–52.
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A. Gastrointestinal toxicity with celecoxib vs nonste-roidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Cele-coxib Long-term Arthritis Safety Study. JAMA. 2000;284: 1247–55.
   Google Scholar
• Scheilman JM, Fendrick AM. Summing the risk of NSAID therapy. Lancet. 2007;369:1580–1.
   PubMed Web of Science ®Google Scholar
• Chan FK, Abraham NS, Scheilman JM, Laine L. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First international working party on gastrointestinal and cardiovascular effects on nonste-roidal anti-inflammatory drugs and anti-platelet agents. Am J Gastroenterol. 2008;103:2908–18.
   PubMed Web of Science ®Google Scholar
• Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil. 2008;16:137–62.
   PubMed Web of Science ®Google Scholar
• Chan FK, Wong VW, Suen BY, Wu JC, Ching JY, Hung LC, et al. Combination of a cyclooxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007;369:1621–6.
   PubMed Web of Science ®Google Scholar
• Miyake K, Ueki N, Suzuki K, Shinji Y, Kusunoki M, Hiratsuka T, et al. Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine. Aliment Pharmacol Ther. 2005;21(Suppl 2):67–72.
   PubMedGoogle Scholar
• US Food and Drug administration (FDA). Possible increased risk of bone fractures with certain antacid drugs. FDA Consumer Health Information. FDA, Washington, D.C., 2010.
   Google Scholar
• Sener G, Goren FO, Ulusoy NB, Ersoy Y, Arbak S, Mager GA. Protective effect of melatonin and omeprazole against alendro-nate-induced gastric damage. Dig Dis Sci. 2005;50:1506–12.
   PubMed Web of Science ®Google Scholar
• Graham DY, Malaty HM. Alendronate and naproxen are syner-gistic for development of gastric ulcers. Arch Intern Med. 2001;161:107–10.
   PubMed Web of Science ®Google Scholar
• Miyake K, Kusunoki M, Shinji Y, Shindo T, Kawagoe T, Futa-gami S, et al. Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal antiinflammatory drug therapy. J Gastroenterol. 2009;44:113–20.
   Google Scholar